When the idea for ACS Pharmacology & Translational Science was just a concept at the American Chemical Society (ACS), I championed the need for a pharmacology and translational science journal within the ACS biological portfolio. I am absolutely thrilled to now have the opportunity to serve as the interim Editor-in-Chief of ACS Pharmacology & Translational Science! ACS Pharmacology & Translational Science (ACS PTSci) is an important and exciting component of the biological portfolio of ACS journals, filling an unmet need to disseminate the latest advances in basic and translational pharmacology across all therapeutic areas and molecular targets. Moreover, ACS Pharmacology & Translational Science provides a new venue for academic researchers, as well as those in the pharmaceutical and biotech industry, to report new assays paradigms, new technologies, target-validation efforts, and human clinical trial monographs in one journal! Launched in late 2018, ACS PTSci currently publishes 6 issues per year. My goal is to increase submissions significantly such that we publish 12 issues per year starting in January 2021. While GPCRs have been, and will continue to be, an area of concentrate for ACS PTSci, I am eager to further expand topical content to include ion channels, kinases, lipases, transporters, nuclear hormone receptors, and biologics, to name just a few. Furthermore, preclinical pharmacology related to epigenetics, immunology, oncology, cardiovascular biology, renal disease, metabolic diseases, and CNS diseases are highly desired. In addition, new advances in preclinical, IND-enabling, and clinical drug metabolism and pharmacokinetics now have a home at ACS. Finally, translational science related to novel biomarker strategies and clinical trial reports (both successful and unsuccessful Phase II/III trials) are appropriate for, and in high demand, at ACS PTSci. ACS PTSci publishes non-peer-reviewed topical Viewpoints and Drug Discovery stories (the “real” story of how a drug was created/developed by the scientists in the trenches and in their own words), as well as peer-reviewed Perspectives, Reviews, Letters, and Articles. ACS PTSci is included in PubMed Central and SCOPUS. ACS Pharmacology & Translational Science has no charges or fees to submit a manuscript or to publish an article under the traditional subscription model (non-open-access). That means no author charges, page charges, processing charges, or color charges. A special issue on preclinical and clinical studies with psychedelics is coming later this fall! I encourage all my colleagues working in the fields of molecular pharmacology and translational sciences in academia and industry to visit the journal homepage and view the amazing science in ACS PTSci. If you have already published with us, then thank you. I hope you send your next manuscript to ACS PTSci. If you had a great past experience, then please tell your colleagues. If you did not have a great experience, then try us again. As EIC, I promise to give your manuscript the highest level of attention, to provide rapid reviews that are fair and balanced, and to expedite the publication process. I am eager to build a community of molecular and clinical pharmacologists within the ACS and using ACS PTSci as a vehicle to disseminate the most important advances in the field. Views expressed in this editorial are those of the author and not necessarily the views of the ACS. This article has not yet been cited by other publications.

中文翻译：

---

ACS药理与转化科学，版本2.0。

当ACS药理学和转化科学的想法只是美国化学学会（ACS）的一个概念时，我主张在ACS生物学产品组合中需要一本药理学和转化科学期刊。我非常高兴现在有机会担任ACS药理学和转化科学的临时总编辑！ACS药理与转化科学（ACS PTSci）是ACS期刊生物学产品组合中重要而令人兴奋的组成部分，满足了在所有治疗领域和分子靶标中传播基础和转化药理学最新进展的未满足需求。此外，ACS药理与转化科学为学术研究人员以及制药和生物技术行业的研究人员提供了一个新的场所，可以在一本期刊中报告新的测定方法范式，新技术，靶标验证工作和人类临床试验专论！ACS PTSci于2018年末推出，目前每年出版6期。我的目标是大幅增加投稿数量，从2021年1月开始，我们每年出版12期。尽管GPCR已经并将继续成为ACS PTSci的重点领域，我急切希望进一步扩展主题内容，包括离子通道，激酶，脂肪酶，转运蛋白，核激素受体和生物制剂等。此外，与表观遗传学，免疫学，肿瘤学，心血管生物学，肾脏疾病，代谢疾病和CNS疾病有关的临床前药理学是非常需要的。此外，ACS在临床前，启用IND以及临床药物代谢和药代动力学方面取得了新进展。最后，与新的生物标志物策略和临床试验报告（成功的/失败的II / III期试验）相关的转化科学适用于ACS PTSci，并且需求很高。ACS PTSci发表未经同行评审的主题观点和药物发现故事（有关科学家如何用trench沟和自己的话来创造/开发药物的“真实”故事），以及经过同行评审的观点，评论，来信和文章。ACS PTSci包含在PubMed Central和SCOPUS中。ACS药理与转化科学在传统订阅模式（非开放访问）下，提交稿件或发表文章不收取任何费用。这意味着不会收取作者费用，页面费用，处理费用或颜色费用。关于迷幻药的临床前和临床研究的特刊将于今年秋天晚些时候发行！我鼓励在学术界和工业界从事分子药理学和转化科学领域的所有同事访问期刊首页，并查看ACS PTSci中令人惊叹的科学。如果您已经在我们这里发表了文章，那么谢谢。希望您将下一篇稿件发送给ACS PTSci。如果您有过往的丰富经验，请告诉您的同事。如果您没有很好的经验，请再试一次。作为EIC，我保证会给予您最高的关注度，以公平，平衡的方式进行快速审查，并加快出版过程。我渴望在ACS内建立分子和临床药理学家社区，并使用ACS PTSci作为传播该领域最重要进展的工具。本社论中表达的观点只是作者的观点，不一定是ACS的观点。本文尚未被其他出版物引用。